文献速递临床免疫质量管理与危急值

10种全自动商用降钙素原免疫检测的两中心比对

Two-center comparison of 10 fully-automated commercial procalcitonin (PCT) immunoassays.
PubMed 文献 · Clin Chem Lab Med · 2019-01-01

该两中心研究将176份常规锂肝素血浆样本等分后,用10种商用降钙素原(PCT)免疫检测法同步测定,评估结果可比性。结果显示各法相关性高(r=0.918~0.997),但偏差变异大(±0.2%~±38.6%),临床决策阈值处一致性有限,低浓度端尤为明显,可能影响PCT的临床价值。

要点

  • 10种商用PCT免疫检测法相关性高,但偏差从±0.2%到±38.6%不等。
  • Diazyme PCT和SNIBE Maglumi PCT高估PCT,Cobas BRAHMS PCT低估。
  • 临床决策阈值处一致性有限,低浓度端差异更明显。

核心结论

  • 10种商用PCT免疫检测法间相关性可接受,但临床决策阈值处一致性有限,低浓度端尤其明显,可能危及该生物标志物的临床价值。

研究设计与样本

  • 两中心研究,将176份常规锂肝素血浆样本等分后同时用10种不同PCT免疫检测法分析。

主要发现

  • 多重比较均显示高度显著相关,相关系数介于0.918和0.997之间(均p < 0.001)。
  • Bland-Altman分析显示免疫检测法间偏差变异大,范围在±0.2%至±38.6%之间。
  • Roche Cobas C702上的Diazyme PCT和SNIBE Maglumi PCT显示较大高估,而Cobas BRAHMS PCT低估PCT值。
  • 一致性均>80%(均p < 0.001),但在0.1 μg/L时为90%-99%,0.25 μg/L时为81%-99%,0.5 μg/L时为83%-100%,2.0 μg/L时为94%-100%,10 μg/L时为90%-99%。
  • Diazyme PCT和Maglumi PCT与其他方法比较时观察到较大不一致。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background This two-center study was designed to verify comparability of procalcitonin (PCT) values among 10 different commercial immunoassays. Methods A total number of 176 routine lithium-heparin plasma samples were divided in identical aliquots and simultaneously analyzed with 10 different PCT immunoassays, including Kryptor BRAHMS PCT sensitive, Abbott Architect BRAHMS PCT, Beckman Coulter Access PCT (on Access and DXI), BioMérieux Vidas BRAHMS PCT, Diasorin Liaison BRAHMS PCT, Fujirebio Lumipulse G BRAHMS PCT, Roche BRAHMS PCT (on Cobas E801), Diazyme PCT (on Roche Cobas C702) and SNIBE Maglumi PCT. Results Highly significant correlation was always found across multiple comparisons, with correlation coefficients comprised between 0.918 and 0.997 (all p < 0.001). Bland and Altman plots analysis revealed highly variable bias among immunoassays, ranging between ±0.2% and ±38.6%. Diazyme PCT on Roche Cobas C702 and SNIBE Maglumi PCT displayed the larger overestimation, whilst PCT values were underestimated by Cobas BRAHAMS PCT. The agreement was always >80% (all p < 0.001), but varied largely across multiple comparisons, ranging between 90%-99% at 0.1 μg/L, 81%-99% at 0.25 μg/L, 83%-100% at 0.5 μg/L, 94%-100% at 2.0 μg/L and 90%-99% at 10 μg/L, respectively. The larger disagreement was observed comparing Diazyme PCT and Maglumi PCT with the other methods. Conclusions Although we found acceptable correlation among 10 commercial PCT immunoassays, the limited agreement at clinical decision thresholds remains a major issue, especially at lower end of PCT concentration, thus potentially contributing to jeopardize the clinical value of this biomarker.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Lippi G, Salvagno GL, Gelati M, et al. Two-center comparison of 10 fully-automated commercial procalcitonin (PCT) immunoassays. Clin Chem Lab Med. 2019. PMID: 31539351. doi:10.1515/cclm-2019-0888

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。